Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-06

AUTHORS

C L White, K R Twigger, L Vidal, J S De Bono, M Coffey, L Heinemann, R Morgan, A Merrick, F Errington, R G Vile, A A Melcher, H S Pandha, K J Harrington

ABSTRACT

There is an emerging realization from animal models that the immune response may have both detrimental and beneficial therapeutic effects during cancer virotherapy. However, there is a dearth of clinical data on the immune response to viral agents in patients. During a recently completed phase I trial of intravenous reovirus type 3 Dearing (RT3D), heavily pretreated patients with advanced cancers received RT3D at doses escalating from 1 x 10(8) tissue culture infectious dose-50 (TCID(50)) on day 1 to 3 x 10(10) TCID(50) on 5 consecutive days of a 4 weekly cycle. A detailed analysis of the immune effects was conducted by collecting serial clinical samples for analysis of neutralizing anti-reoviral antibodies (NARA), peripheral blood mononuclear cells (PBMC) and cytokines. Significant increases in NARA were seen with peak endpoint titres >1/10 000 in all but one patient. The median fold increase was 250, with a range of 9-6437. PBMC subset analysis showed marked heterogeneity. At baseline, CD3+CD4+ T cells were reduced in most patients, but after RT3D therapy their numbers increased in 47.6% of patients. In contrast, most patients had high baseline CD3+CD8+ T-cell levels, with 33% showing incremental increases after therapy. In some patients, there was increased cytotoxic T-cell activation post-therapy, as shown by increased CD8+perforin/granzyme+ T-cell numbers. Most patients had high numbers of circulating CD3-CD56+ NK cells before therapy and in 28.6% this increased with treatment. Regulatory (CD3+CD4+CD25+) T cells were largely unaffected by the therapy. Combined Th1 and Th2 cytokine expression increased in 38% of patients. These data confirm that even heavily pretreated patients are capable of mounting dynamic immune responses during treatment with RT3D, although these responses are not clearly related to the administered virus dose. These data will provide the basis for future studies aiming to modulate the immune response during virotherapy. More... »

PAGES

gt200821

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/gt.2008.21

DOI

http://dx.doi.org/10.1038/gt.2008.21

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008460464

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18323793


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytokines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunity, Innate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mammalian orthoreovirus 3", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oncolytic Virotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocyte Subsets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "The Institute of Cancer Research, Cancer Research UK Center for Cell and Molecular Biology, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "White", 
        "givenName": "C L", 
        "id": "sg:person.012523221567.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012523221567.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "The Institute of Cancer Research, Cancer Research UK Center for Cell and Molecular Biology, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Twigger", 
        "givenName": "K R", 
        "id": "sg:person.01260231270.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260231270.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "The Institute of Cancer Research, Cancer Research UK Center for Cell and Molecular Biology, London, UK", 
            "Drug Development Unit, The Royal Marsden Hospital NHS Foundation Trust, London and Sutton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vidal", 
        "givenName": "L", 
        "id": "sg:person.01007541170.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007541170.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Drug Development Unit, The Royal Marsden Hospital NHS Foundation Trust, London and Sutton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Bono", 
        "givenName": "J S", 
        "id": "sg:person.01204004306.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204004306.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncolytics Biotech (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.459870.7", 
          "name": [
            "Oncolytics Biotech Inc., Calgary, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coffey", 
        "givenName": "M", 
        "id": "sg:person.01014326765.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014326765.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Surrey", 
          "id": "https://www.grid.ac/institutes/grid.5475.3", 
          "name": [
            "Postgraduate Medical School, University of Surrey, Guildford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heinemann", 
        "givenName": "L", 
        "id": "sg:person.0715165735.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715165735.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Leeds Institute of Molecular Medicine, St James\u2018s University Hospital, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morgan", 
        "givenName": "R", 
        "id": "sg:person.016516371462.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016516371462.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Leeds Institute of Molecular Medicine, St James\u2018s University Hospital, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Merrick", 
        "givenName": "A", 
        "id": "sg:person.01255771754.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255771754.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Leeds Institute of Molecular Medicine, St James\u2018s University Hospital, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Errington", 
        "givenName": "F", 
        "id": "sg:person.0671466105.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671466105.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vile", 
        "givenName": "R G", 
        "id": "sg:person.01207711633.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207711633.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Leeds Institute of Molecular Medicine, St James\u2018s University Hospital, University of Leeds, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Melcher", 
        "givenName": "A A", 
        "id": "sg:person.01266210711.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266210711.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Surrey", 
          "id": "https://www.grid.ac/institutes/grid.5475.3", 
          "name": [
            "Postgraduate Medical School, University of Surrey, Guildford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pandha", 
        "givenName": "H S", 
        "id": "sg:person.01215757170.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215757170.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "The Institute of Cancer Research, Cancer Research UK Center for Cell and Molecular Biology, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrington", 
        "givenName": "K J", 
        "id": "sg:person.01167312032.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167312032.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/eji.1830251239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001746180"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jgm.885", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004292605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jgm.885", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004292605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.4116", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005519983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/emboj/17.12.3351", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025374400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/428911", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027910870"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-04-0940", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028314268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01314776", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031705085", 
          "https://doi.org/10.1007/bf01314776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01314776", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031705085", 
          "https://doi.org/10.1007/bf01314776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3300508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033780095", 
          "https://doi.org/10.1038/sj.gt.3300508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3300508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033780095", 
          "https://doi.org/10.1038/sj.gt.3300508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/327293a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035638144", 
          "https://doi.org/10.1038/327293a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-3974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038922605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.2910430614", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048066079"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3302935", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050168915", 
          "https://doi.org/10.1038/sj.gt.3302935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3302935", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050168915", 
          "https://doi.org/10.1038/sj.gt.3302935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.282.5392.1332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062563200"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075223339", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.aje.a120293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076160879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.aje.a120109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076520795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079524507", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079666947", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079759531", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.5.1690", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082882845"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-06", 
    "datePublishedReg": "2008-06-01", 
    "description": "There is an emerging realization from animal models that the immune response may have both detrimental and beneficial therapeutic effects during cancer virotherapy. However, there is a dearth of clinical data on the immune response to viral agents in patients. During a recently completed phase I trial of intravenous reovirus type 3 Dearing (RT3D), heavily pretreated patients with advanced cancers received RT3D at doses escalating from 1 x 10(8) tissue culture infectious dose-50 (TCID(50)) on day 1 to 3 x 10(10) TCID(50) on 5 consecutive days of a 4 weekly cycle. A detailed analysis of the immune effects was conducted by collecting serial clinical samples for analysis of neutralizing anti-reoviral antibodies (NARA), peripheral blood mononuclear cells (PBMC) and cytokines. Significant increases in NARA were seen with peak endpoint titres >1/10 000 in all but one patient. The median fold increase was 250, with a range of 9-6437. PBMC subset analysis showed marked heterogeneity. At baseline, CD3+CD4+ T cells were reduced in most patients, but after RT3D therapy their numbers increased in 47.6% of patients. In contrast, most patients had high baseline CD3+CD8+ T-cell levels, with 33% showing incremental increases after therapy. In some patients, there was increased cytotoxic T-cell activation post-therapy, as shown by increased CD8+perforin/granzyme+ T-cell numbers. Most patients had high numbers of circulating CD3-CD56+ NK cells before therapy and in 28.6% this increased with treatment. Regulatory (CD3+CD4+CD25+) T cells were largely unaffected by the therapy. Combined Th1 and Th2 cytokine expression increased in 38% of patients. These data confirm that even heavily pretreated patients are capable of mounting dynamic immune responses during treatment with RT3D, although these responses are not clearly related to the administered virus dose. These data will provide the basis for future studies aiming to modulate the immune response during virotherapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/gt.2008.21", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1105638", 
        "issn": [
          "0969-7128", 
          "1476-5462"
        ], 
        "name": "Gene Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial", 
    "pagination": "gt200821", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "284e1ccf77375ab61e91769fc26a8727bf00599b155b00268cb0634511fae3d8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18323793"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9421525"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/gt.2008.21"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008460464"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/gt.2008.21", 
      "https://app.dimensions.ai/details/publication/pub.1008460464"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000422.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.nature.com/articles/gt200821"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/gt.2008.21'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/gt.2008.21'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/gt.2008.21'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/gt.2008.21'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      21 PREDICATES      67 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/gt.2008.21 schema:about N0acf6dd6ac50470f97fdcdc68a41bb33
2 N174a4ba67d7f4e188eca59b60a8185e3
3 N1c51cf908e204ca4a2d01782eae2fa5d
4 N4af024d71fe34abba4368c1905dbf795
5 N4c5f3beff57a4d45965018b570db5541
6 N689899b5ddc640b185ef84d12dce2bf1
7 N90c6606bd8e74e4d88fc36ab7e207927
8 N97cffadba91846d9ba3ba6ab1345df9b
9 Na292280eb1dc4099b3f7f512947299ee
10 Nac719fca366c42e28465ee387a134e7d
11 Nbad84098b07540aeab62e328df98c9a1
12 Nca319349094a4e42a69a251d98716e6a
13 Ncc2e7e21feec49e9ae0edfc30d53a023
14 Nd6bbc4bb6044477ca028448f09236e5c
15 Ned7bcded661d4337aca86b933afb289e
16 Nf3e6271e76cd4161bfc4cbbd8c294c39
17 Nf5522d0189e24f82a0ce6b77ad3ed200
18 Nfb6d7be796db4197bd455e2402c6aaac
19 anzsrc-for:11
20 anzsrc-for:1107
21 schema:author Ne7a84e6a2ac14aedb7ea3e55f12c1f31
22 schema:citation sg:pub.10.1007/bf01314776
23 sg:pub.10.1038/327293a0
24 sg:pub.10.1038/sj.gt.3300508
25 sg:pub.10.1038/sj.gt.3302935
26 https://app.dimensions.ai/details/publication/pub.1075223339
27 https://app.dimensions.ai/details/publication/pub.1079524507
28 https://app.dimensions.ai/details/publication/pub.1079666947
29 https://app.dimensions.ai/details/publication/pub.1079759531
30 https://doi.org/10.1002/eji.1830251239
31 https://doi.org/10.1002/ijc.2910430614
32 https://doi.org/10.1002/jgm.885
33 https://doi.org/10.1086/428911
34 https://doi.org/10.1093/emboj/17.12.3351
35 https://doi.org/10.1093/oxfordjournals.aje.a120109
36 https://doi.org/10.1093/oxfordjournals.aje.a120293
37 https://doi.org/10.1126/science.282.5392.1332
38 https://doi.org/10.1158/0008-5472.can-06-3974
39 https://doi.org/10.1158/1078-0432.ccr-04-0940
40 https://doi.org/10.1200/jco.1996.14.5.1690
41 https://doi.org/10.1200/jco.2005.03.4116
42 schema:datePublished 2008-06
43 schema:datePublishedReg 2008-06-01
44 schema:description There is an emerging realization from animal models that the immune response may have both detrimental and beneficial therapeutic effects during cancer virotherapy. However, there is a dearth of clinical data on the immune response to viral agents in patients. During a recently completed phase I trial of intravenous reovirus type 3 Dearing (RT3D), heavily pretreated patients with advanced cancers received RT3D at doses escalating from 1 x 10(8) tissue culture infectious dose-50 (TCID(50)) on day 1 to 3 x 10(10) TCID(50) on 5 consecutive days of a 4 weekly cycle. A detailed analysis of the immune effects was conducted by collecting serial clinical samples for analysis of neutralizing anti-reoviral antibodies (NARA), peripheral blood mononuclear cells (PBMC) and cytokines. Significant increases in NARA were seen with peak endpoint titres >1/10 000 in all but one patient. The median fold increase was 250, with a range of 9-6437. PBMC subset analysis showed marked heterogeneity. At baseline, CD3+CD4+ T cells were reduced in most patients, but after RT3D therapy their numbers increased in 47.6% of patients. In contrast, most patients had high baseline CD3+CD8+ T-cell levels, with 33% showing incremental increases after therapy. In some patients, there was increased cytotoxic T-cell activation post-therapy, as shown by increased CD8+perforin/granzyme+ T-cell numbers. Most patients had high numbers of circulating CD3-CD56+ NK cells before therapy and in 28.6% this increased with treatment. Regulatory (CD3+CD4+CD25+) T cells were largely unaffected by the therapy. Combined Th1 and Th2 cytokine expression increased in 38% of patients. These data confirm that even heavily pretreated patients are capable of mounting dynamic immune responses during treatment with RT3D, although these responses are not clearly related to the administered virus dose. These data will provide the basis for future studies aiming to modulate the immune response during virotherapy.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree true
48 schema:isPartOf N64a26fe8506047beadfdbfee7c0ecd01
49 Nb3dc2fea197747adbfb7ab8f5685532b
50 sg:journal.1105638
51 schema:name Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
52 schema:pagination gt200821
53 schema:productId N047dd12fdd6d4a4dac9ddd70b58ab646
54 N0d43a71c3e4a464a825ed4fa04f6e585
55 N2c79a84b4288400587d2ccb10b66a5cc
56 N2f1d7bd97ddf4b9ea278b23ad16a29b5
57 N658fe3da1b974aa5a776a0bc023bd750
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008460464
59 https://doi.org/10.1038/gt.2008.21
60 schema:sdDatePublished 2019-04-10T15:38
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N16617543f7b84a878f90bcffb6e066c4
63 schema:url http://www.nature.com/articles/gt200821
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N047dd12fdd6d4a4dac9ddd70b58ab646 schema:name pubmed_id
68 schema:value 18323793
69 rdf:type schema:PropertyValue
70 N0acf6dd6ac50470f97fdcdc68a41bb33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Immunity, Innate
72 rdf:type schema:DefinedTerm
73 N0d43a71c3e4a464a825ed4fa04f6e585 schema:name nlm_unique_id
74 schema:value 9421525
75 rdf:type schema:PropertyValue
76 N108cb6b7f05849c8bafb03565443bc6c rdf:first sg:person.01215757170.08
77 rdf:rest N2efdf76c52cc4815a2028defe1aca657
78 N16617543f7b84a878f90bcffb6e066c4 schema:name Springer Nature - SN SciGraph project
79 rdf:type schema:Organization
80 N174a4ba67d7f4e188eca59b60a8185e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Treatment Outcome
82 rdf:type schema:DefinedTerm
83 N17d0e04955264ef5b2b5c2b1b29bb408 rdf:first sg:person.01207711633.71
84 rdf:rest N927af9ef42a94bec820a91444ee7e54f
85 N1c51cf908e204ca4a2d01782eae2fa5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Adult
87 rdf:type schema:DefinedTerm
88 N1f3b438fa0df4554b3d5a2e395891cf0 rdf:first sg:person.01204004306.08
89 rdf:rest N9c41d9a6a7eb4c97996de5e8f9957ce1
90 N2c79a84b4288400587d2ccb10b66a5cc schema:name readcube_id
91 schema:value 284e1ccf77375ab61e91769fc26a8727bf00599b155b00268cb0634511fae3d8
92 rdf:type schema:PropertyValue
93 N2e681df8afba45899ec23a03b748f48e schema:name Leeds Institute of Molecular Medicine, St James‘s University Hospital, University of Leeds, Leeds, UK
94 rdf:type schema:Organization
95 N2efdf76c52cc4815a2028defe1aca657 rdf:first sg:person.01167312032.35
96 rdf:rest rdf:nil
97 N2f1d7bd97ddf4b9ea278b23ad16a29b5 schema:name doi
98 schema:value 10.1038/gt.2008.21
99 rdf:type schema:PropertyValue
100 N383707c9919745fa899ef73fdd31d174 schema:name Leeds Institute of Molecular Medicine, St James‘s University Hospital, University of Leeds, Leeds, UK
101 rdf:type schema:Organization
102 N40e1c4c2ef70472ead8b56f81151c284 rdf:first sg:person.016516371462.67
103 rdf:rest Nc3355cef7ff349339efb134dd3bc2d0d
104 N4af024d71fe34abba4368c1905dbf795 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name T-Lymphocyte Subsets
106 rdf:type schema:DefinedTerm
107 N4ba68d33f1ee4795811e96282fff9286 rdf:first sg:person.0715165735.86
108 rdf:rest N40e1c4c2ef70472ead8b56f81151c284
109 N4c5f3beff57a4d45965018b570db5541 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Lymphocyte Count
111 rdf:type schema:DefinedTerm
112 N64a26fe8506047beadfdbfee7c0ecd01 schema:volumeNumber 15
113 rdf:type schema:PublicationVolume
114 N658fe3da1b974aa5a776a0bc023bd750 schema:name dimensions_id
115 schema:value pub.1008460464
116 rdf:type schema:PropertyValue
117 N67f4d25a9bf6413186b4da078e86a964 schema:name Leeds Institute of Molecular Medicine, St James‘s University Hospital, University of Leeds, Leeds, UK
118 rdf:type schema:Organization
119 N689899b5ddc640b185ef84d12dce2bf1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Cytokines
121 rdf:type schema:DefinedTerm
122 N68f210ad27464724a412d8d0881a667d rdf:first sg:person.01007541170.08
123 rdf:rest N1f3b438fa0df4554b3d5a2e395891cf0
124 N7bbf9dcaaead494287d69f89000abd64 rdf:first sg:person.0671466105.84
125 rdf:rest N17d0e04955264ef5b2b5c2b1b29bb408
126 N7bd9475eba7d499086f6ee7cd122a375 rdf:first sg:person.01260231270.15
127 rdf:rest N68f210ad27464724a412d8d0881a667d
128 N90c6606bd8e74e4d88fc36ab7e207927 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Neoplasms
130 rdf:type schema:DefinedTerm
131 N927af9ef42a94bec820a91444ee7e54f rdf:first sg:person.01266210711.38
132 rdf:rest N108cb6b7f05849c8bafb03565443bc6c
133 N97cffadba91846d9ba3ba6ab1345df9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Mammalian orthoreovirus 3
135 rdf:type schema:DefinedTerm
136 N9c41d9a6a7eb4c97996de5e8f9957ce1 rdf:first sg:person.01014326765.89
137 rdf:rest N4ba68d33f1ee4795811e96282fff9286
138 Na292280eb1dc4099b3f7f512947299ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Injections, Intravenous
140 rdf:type schema:DefinedTerm
141 Nac719fca366c42e28465ee387a134e7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Male
143 rdf:type schema:DefinedTerm
144 Nb3dc2fea197747adbfb7ab8f5685532b schema:issueNumber 12
145 rdf:type schema:PublicationIssue
146 Nbad84098b07540aeab62e328df98c9a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Genetic Therapy
148 rdf:type schema:DefinedTerm
149 Nc030faea85854aaea40649d8101cf40c schema:name Leeds Institute of Molecular Medicine, St James‘s University Hospital, University of Leeds, Leeds, UK
150 rdf:type schema:Organization
151 Nc3355cef7ff349339efb134dd3bc2d0d rdf:first sg:person.01255771754.38
152 rdf:rest N7bbf9dcaaead494287d69f89000abd64
153 Nca319349094a4e42a69a251d98716e6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Aged
155 rdf:type schema:DefinedTerm
156 Ncc2e7e21feec49e9ae0edfc30d53a023 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Humans
158 rdf:type schema:DefinedTerm
159 Nd6bbc4bb6044477ca028448f09236e5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Middle Aged
161 rdf:type schema:DefinedTerm
162 Ne7a84e6a2ac14aedb7ea3e55f12c1f31 rdf:first sg:person.012523221567.24
163 rdf:rest N7bd9475eba7d499086f6ee7cd122a375
164 Ned7bcded661d4337aca86b933afb289e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Aged, 80 and over
166 rdf:type schema:DefinedTerm
167 Nf3e6271e76cd4161bfc4cbbd8c294c39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antibodies, Viral
169 rdf:type schema:DefinedTerm
170 Nf5522d0189e24f82a0ce6b77ad3ed200 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Female
172 rdf:type schema:DefinedTerm
173 Nfb6d7be796db4197bd455e2402c6aaac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Oncolytic Virotherapy
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
180 schema:name Immunology
181 rdf:type schema:DefinedTerm
182 sg:journal.1105638 schema:issn 0969-7128
183 1476-5462
184 schema:name Gene Therapy
185 rdf:type schema:Periodical
186 sg:person.01007541170.08 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
187 schema:familyName Vidal
188 schema:givenName L
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007541170.08
190 rdf:type schema:Person
191 sg:person.01014326765.89 schema:affiliation https://www.grid.ac/institutes/grid.459870.7
192 schema:familyName Coffey
193 schema:givenName M
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014326765.89
195 rdf:type schema:Person
196 sg:person.01167312032.35 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
197 schema:familyName Harrington
198 schema:givenName K J
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167312032.35
200 rdf:type schema:Person
201 sg:person.01204004306.08 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
202 schema:familyName De Bono
203 schema:givenName J S
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204004306.08
205 rdf:type schema:Person
206 sg:person.01207711633.71 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
207 schema:familyName Vile
208 schema:givenName R G
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207711633.71
210 rdf:type schema:Person
211 sg:person.01215757170.08 schema:affiliation https://www.grid.ac/institutes/grid.5475.3
212 schema:familyName Pandha
213 schema:givenName H S
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215757170.08
215 rdf:type schema:Person
216 sg:person.012523221567.24 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
217 schema:familyName White
218 schema:givenName C L
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012523221567.24
220 rdf:type schema:Person
221 sg:person.01255771754.38 schema:affiliation N67f4d25a9bf6413186b4da078e86a964
222 schema:familyName Merrick
223 schema:givenName A
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255771754.38
225 rdf:type schema:Person
226 sg:person.01260231270.15 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
227 schema:familyName Twigger
228 schema:givenName K R
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260231270.15
230 rdf:type schema:Person
231 sg:person.01266210711.38 schema:affiliation N383707c9919745fa899ef73fdd31d174
232 schema:familyName Melcher
233 schema:givenName A A
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266210711.38
235 rdf:type schema:Person
236 sg:person.016516371462.67 schema:affiliation N2e681df8afba45899ec23a03b748f48e
237 schema:familyName Morgan
238 schema:givenName R
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016516371462.67
240 rdf:type schema:Person
241 sg:person.0671466105.84 schema:affiliation Nc030faea85854aaea40649d8101cf40c
242 schema:familyName Errington
243 schema:givenName F
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671466105.84
245 rdf:type schema:Person
246 sg:person.0715165735.86 schema:affiliation https://www.grid.ac/institutes/grid.5475.3
247 schema:familyName Heinemann
248 schema:givenName L
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715165735.86
250 rdf:type schema:Person
251 sg:pub.10.1007/bf01314776 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031705085
252 https://doi.org/10.1007/bf01314776
253 rdf:type schema:CreativeWork
254 sg:pub.10.1038/327293a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035638144
255 https://doi.org/10.1038/327293a0
256 rdf:type schema:CreativeWork
257 sg:pub.10.1038/sj.gt.3300508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033780095
258 https://doi.org/10.1038/sj.gt.3300508
259 rdf:type schema:CreativeWork
260 sg:pub.10.1038/sj.gt.3302935 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050168915
261 https://doi.org/10.1038/sj.gt.3302935
262 rdf:type schema:CreativeWork
263 https://app.dimensions.ai/details/publication/pub.1075223339 schema:CreativeWork
264 https://app.dimensions.ai/details/publication/pub.1079524507 schema:CreativeWork
265 https://app.dimensions.ai/details/publication/pub.1079666947 schema:CreativeWork
266 https://app.dimensions.ai/details/publication/pub.1079759531 schema:CreativeWork
267 https://doi.org/10.1002/eji.1830251239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001746180
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1002/ijc.2910430614 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048066079
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1002/jgm.885 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004292605
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1086/428911 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027910870
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1093/emboj/17.12.3351 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025374400
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1093/oxfordjournals.aje.a120109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076520795
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1093/oxfordjournals.aje.a120293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076160879
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1126/science.282.5392.1332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062563200
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1158/0008-5472.can-06-3974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038922605
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1158/1078-0432.ccr-04-0940 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028314268
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1200/jco.1996.14.5.1690 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082882845
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1200/jco.2005.03.4116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005519983
290 rdf:type schema:CreativeWork
291 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
292 schema:name The Institute of Cancer Research, Cancer Research UK Center for Cell and Molecular Biology, London, UK
293 rdf:type schema:Organization
294 https://www.grid.ac/institutes/grid.459870.7 schema:alternateName Oncolytics Biotech (Canada)
295 schema:name Oncolytics Biotech Inc., Calgary, Canada
296 rdf:type schema:Organization
297 https://www.grid.ac/institutes/grid.5072.0 schema:alternateName Royal Marsden NHS Foundation Trust
298 schema:name Drug Development Unit, The Royal Marsden Hospital NHS Foundation Trust, London and Sutton, UK
299 The Institute of Cancer Research, Cancer Research UK Center for Cell and Molecular Biology, London, UK
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.5475.3 schema:alternateName University of Surrey
302 schema:name Postgraduate Medical School, University of Surrey, Guildford, UK
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.66875.3a schema:alternateName Mayo Clinic
305 schema:name Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...